DRL-Header DRL-Header

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Oncology Drugs in Phase I/II Clinical Development in TAIWAN

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size
            filter Upfront Payment

              Active Filter(s):

              refreshReset Filter
              refresh Reset Filter
              price-trend All Drugs in Dev.

              Product Type

              Companies

              Senhwa Biosciences

              • Development Update

              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

              Post an Enquiry Post an Enquiry
              Flag Taiwan
              Virtual Booth Virtual Booth
              Digital Content Digital Content
              Digital Content Digital Content

              CPhI Middle East & Africa 2021

              Participation Not Confirmed

              Update your events

              Senhwa's Silmitasertib Receives US FDA Fast Track Designation for the Treatment of Re...

              Lead Product(s): Silmitasertib

              Therapeutic Area: Oncology Product Name: CX-4945

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Pediatric Brain Tumor Consortium

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 17, 2021

              Details:

              Senhwa’s clinical partner, the Pediatric Brain Tumor Consortium, is currently conducting a Phase I/II and Surgical Study of Silmitasertib in both children and adults with recurrent SHH Medulloblastoma.